(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Basic information
- Product Name:
- (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID
- Synonyms:
-
- (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID
- (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID: HYDROCHLORIDE
- ACE/TA-6366
- Novarok
- SH-6366
- Imidaprilhydrochloride
- 4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, monohydrochloride, (4S)-
- 4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, monohydrochloride, [4S-[3[R*(R*)],4R*]]-
- CAS:
- 89396-94-1
- MF:
- C20H27N3O6
- MW:
- 405.44488
- EINECS:
- 685-551-0
- Product Categories:
-
- Inhibitors
- Mol File:
- 89396-94-1.mol
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Chemical Properties
- Melting point:
- 214-216℃
- alpha
- D20 -64.1° (c = 0.5 in ethanol)
- storage temp.
- -20°C
- solubility
- H2O: ≥5mg/mL
- form
- powder
- color
- white to tan
- optical activity
- [α]/D -50 to -70° in ethanol (c=0.5)
- Merck
- 14,4911
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Usage And Synthesis
Uses
Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.
Uses
Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive.
Uses
antibiotic
Definition
ChEBI: Imidapril hydrochloride is a dipeptide.
General Description
Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.
Biochem/physiol Actions
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.
Clinical Use
Angiotensin-converting enzyme inhibitor:
Hypertension
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion, possibility of enhanced
lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity.
Metabolism
Imidapril is a prodrug, and is metabolised in the liver
to the diacid imidaprilat, its active metabolite. The
bioavailability of imidaprilat is about 42% after oral doses
of imidapril.
About 40% of an oral dose is excreted in the urine, the
rest in the faeces.
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACIDSupplier
- Tel
- 15502154572
- yuben012@sina.com
- Tel
- 13817811078
- sales@jingyan-chemical.com
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 0571-82693216
- info@yuhaochemical.com
- Tel
- 010-56205725
- waley188@sohu.com